Article By:
ChinaBio® Today
Saturday, July 23, 2022 1:40 PM EDT
WuXi Biologics and WuXi AppTec announced that each company would invest $1.4 billion over ten years to build R&D and manufacturing facilities in Singapore. Frontera Therapeutics completed a $160 million Series B funding to support its AAV programs.